3 registrations that name goji berry as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT06237127
Effects of Goji vs. Fiber on Macular Degeneration
No phase
University of California, Davis
About 60 people
Started Apr 29, 2024
In plain words A study of goji berry in people 65 to 95, run by University of California, Davis. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 95; healthy volunteers accepted. Conditions: Age-Related Macular Degeneration.
Family history of AMD
Hyperlipidemia or managed diabetes
65 - 95 years of age
The exclusion criteria are on the listing.
What it tests, as registered
Goji berry; Fiber
Registered summary
The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.
Where, as registered
1 US site in 1 state.
RecruitingNCT07842536
Efficacy of Lycium Barbarum Polysaccharide in Dry Eye Disease Management
No phase
The Hong Kong Polytechnic University
About 30 people
Starts Sep 14, 2026 (estimated)
In plain words A study of goji berry in people 18 to 60, run by The Hong Kong Polytechnic University. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Dry Eye Syndromes.
Age 18 to 60 years at enrollment.
Clinical diagnosis of dry eye disease, defined as OSDI-12 score >=13 and at least one clinical sign of dry eye disease.
Habitual visual acuity 6/9 or better in both eyes.
Able to understand the study procedures and provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Lycium Barbarum Polysaccharide
Registered summary
The goal of this pilot clinical study is to learn if Lycium barbarum polysaccharide (LBP) supplementation helps manage dry eye disease in adults. It will also learn about the safety of LBP supplementation. The main questions it aims to answer are: 1. Does LBP supplementation improve dry eye symptoms after 12 weeks? 2. Does LBP supplementation improve clinical signs of dry eye disease, such as tear film stability, tear production, and ocular surface staining? Researchers will evaluate changes in dry eye symptoms and eye examination results before and after LBP supplementation. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
Not yet recruitingNCT07660315
Goji Berry and Vasomotor Symptoms Pilot Study
No phase
University of California, Davis
About 6 people
Starts Oct 25, 2026 (estimated)
In plain words A study of goji berry in female participants 40 to 65, run by University of California, Davis. It plans to enroll about 6 people at 1 US site.
Peri- or postmenopausal with vasomotor symptoms (hot flashes) occurring ≥4 days/week over the past 2 weeks
Willing to consume one mug-cake daily for 30 days
Willing to complete daily VMS symptom tracking on a smartphone
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Goji Berry Juice Powder; Goji Berry Powder
Registered summary
The goal of this clinical trial is to compare two forms of goji berry powder-whole goji berry powder and goji juice powder-in peri- and postmenopausal women aged 40-65 years who experience frequent vasomotor symptoms (hot flashes). The study aims to determine which formulation is more promising for a future larger trial by evaluating effects on HDL cholesterol function, vasomotor symptoms, cognitive performance, and participant acceptability. The full summary is on the listing.